Novocure (tumor treating fields)
HAYES, Inc.
Record ID 32016000778
English
Authors' recommendations:
Purpose of Technology: Novocure (also referred to as Optune or NovoTFF-100A System) is a novel device that emits alternating electric fields that disrupt the rapid cell division exhibited by cancer cells. Novocure has been approved for use in patients with recurrent glioblastoma (GBM) or as a concomitant treatment with temozolomide (TMZ) in patients with newly diagnosed GBM. Its use has also been investigated within clinical trials in patients with cancers other than GBM, including non-small cell lung cancer (NSCLC).
Relevant Questions: Is Novocure effective in increasing survival and quality of life in patients with GBM and other solid tumors? Is Novocure safe? Have definitive patient selection criteria been established for patients with GBM and other cancers treated with Novocure?
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=39286
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Brain Neoplasms
- Glioblastoma
- Carcinoma, Non-Small-Cell Lung
- Patient Selection
- Quality of Life
- Electric Stimulation Therapy
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
<p>HAYES, Inc.</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.